Watts Ryan J.'s Form 4 filing
Denali Therapeutics Inc. (DNLI) · filed Feb 15, 2023
- Accession no.
- 0001714899-23-000029
- Filed
- Feb 15, 2023
- Trade date
- Feb 13, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.02M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Watts Ryan J.CIK 0001724310 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 13, 2023 | Common Stock | SSaleDisposed | −8,815 | $30.09F2 | −$265,243.35 | 2,239,913 | Indirect | |
| Feb 13, 2023 | Common Stock | MOption exerciseAcquired | +25,000 | $0.68 | +$17,000 | 2,264,913 | Indirect | |
| Feb 13, 2023 | Common Stock | SSaleDisposed | −25,000 | $30.08F6 | −$752,000 | 2,239,913 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 13, 2023 | Common Stock | MOption exerciseDisposed | −25,000 | $0.00 | $0 | 1,195,617 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.95 to $30.24 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F6
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.26 per share. Upon request by the Commission staff, the Issuer, or asecurityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.